C4 Therapeutics, Inc.
CCCC- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001662579
No open-market purchases or sales by C4 Therapeutics, Inc. insiders were filed in the last 90 days; 147 institutions reported holding it in 13F filings for Q2 2026, worth $547.6M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, +24 vs. previous quarter
- 147
- 13F valueReported value at the end of Q2 2026
- $547.6M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CCCC, Q2 2026
No superinvestor reported holding CCCC at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by C4 Therapeutics, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 16, 2026 (view filing) | Jan 16 | Same day | Reyno LeonardChief Medical Officer | SSale | −10.0K | $2.22 | −$22.2K | −6.0%156.4K after | |
| Feb 18, 2025 (view filing) | Feb 14-18 | 4 days | Boyle Scott NChief Business Officer | SSale | −1.16K | $3.15 | −$3.65K | −1.1%107.8K after | 2 lots10b5-1 |
| Feb 10, 2023 (view filing) | Feb 8 | 2 days | Koppikar UtpalDirector | PPurchase | +5.67K | $5.60 | +$31.7K | New position5.67K after | |
| Apr 12, 2022 (view filing) | Apr 12 | Same day | Hirsch AndrewPresident & CEO | PPurchase | +10.0K | $8.40 | +$84.0K | New position10.0K after | |
| Jan 5, 2022 (view filing) | Jan 4 | 1 day | Crystal AdamChief Medical Officer | SSale | −15.0K | $31.67 | −$475.0K | −50.0%15.0K after | 2 lots |
| Dec 17, 2021 (view filing) | Dec 17 | Same day | Salter MalcolmDirector | SSale | −755 | $30.25 | −$22.8K | −6.4%11.0K after | |
| Nov 19, 2021 (view filing) | Nov 19 | Same day | Salter MalcolmDirector | SSale | −755 | $40.11 | −$30.3K | −6.1%11.7K after | |
| Oct 15, 2021 (view filing) | Oct 15 | Same day | Salter MalcolmDirector | SSale | −755 | $44.94 | −$33.9K | −5.7%12.5K after | |
| Oct 5, 2021 (view filing) | Oct 1 | 4 days | Crystal AdamChief Medical Officer | SSale | −15.0K | $45.43 | −$681.4K | −100.0%0 after | 3 lots |
| Sep 29, 2021 (view filing) | Sep 27 | 2 days | Prokupets ElenaDirector | SSale | −1.85K | $50.04 | −$92.6K | −0.4%503.1K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in C4 Therapeutics, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Morgan Stanley | 8,867,338 | $41.4M | 0.00% | −205,062−2.3% | Reduced |
| Ra Capital Management, L.P. | 8,000,000 | $37.4M | 0.32% | 00.0% | Unchanged |
| BlackRock, Inc. | 7,896,718 | $36.9M | 0.00% | +5,848,192+285.5% | Added |
| Lynx1 Capital Management LP | 7,326,691 | $34.2M | 3.95% | +327,789+4.7% | Added |
| Squadron Capital Management LLC | 7,200,000 | $33.6M | 11.51% | +4,950,000+220.0% | Added |
| Bain Capital Life Sciences Investors, LLC | 7,171,910 | $33.5M | 1.99% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 4,747,424 | $20.7M | 0.00% | +1,524,370+47.3% | Added |
| Vanguard Capital Management LLC | 4,417,731 | $20.6M | 0.00% | +555,879+14.4% | Added |
| Citadel Advisors LLC | 4,187,580 | $19.6M | 0.01% | +1,676,565+66.8% | Added |
| Goldman Sachs Group Inc | 3,530,991 | $16.5M | 0.00% | +1,143,613+47.9% | Added |